Mycolactone-mediated inhibition of tumor necrosis factor production by macrophages infected with Mycobacterium ulcerans has implications for the control of infection
- PMID: 17517872
- PMCID: PMC1951989
- DOI: 10.1128/IAI.00290-07
Mycolactone-mediated inhibition of tumor necrosis factor production by macrophages infected with Mycobacterium ulcerans has implications for the control of infection
Abstract
The pathogenicity of Mycobacterium ulcerans, the agent of Buruli ulcer, depends on the cytotoxic exotoxin mycolactone. Little is known about the immune response to this pathogen. Following the demonstration of an intracellular growth phase in the life cycle of M. ulcerans, we investigated the production of tumor necrosis factor (TNF) induced by intramacrophage bacilli of diverse toxigenesis/virulence, as well as the biological relevance of TNF during M. ulcerans experimental infections. Our data show that murine bone marrow-derived macrophages infected with mycolactone-negative strains of M. ulcerans (nonvirulent) produce high amounts of TNF, while macrophages infected with mycolactone-positive strains of intermediate or high virulence produce intermediate or low amounts of TNF, respectively. These results are in accordance with the finding that TNF receptor P55-deficient (TNF-P55 KO) mice are not more susceptible than wild-type mice to infection by the highly virulent strains but are more susceptible to nonvirulent and intermediately virulent strains, demonstrating that TNF is required to control the proliferation of these strains in animals experimentally infected by M. ulcerans. We also show that mycolactone produced by intramacrophage M. ulcerans bacilli inhibits, in a dose-dependent manner, but does not abrogate, the production of macrophage inflammatory protein 2, which is consistent with the persistent inflammatory responses observed in experimentally infected mice.
Figures






Similar articles
-
Evidence for an intramacrophage growth phase of Mycobacterium ulcerans.Infect Immun. 2007 Feb;75(2):977-87. doi: 10.1128/IAI.00889-06. Epub 2006 Dec 4. Infect Immun. 2007. PMID: 17145944 Free PMC article.
-
IFN-gamma-dependent activation of macrophages during experimental infections by Mycobacterium ulcerans is impaired by the toxin mycolactone.J Immunol. 2010 Jan 15;184(2):947-55. doi: 10.4049/jimmunol.0902717. Epub 2009 Dec 11. J Immunol. 2010. PMID: 20008288
-
Mycobacterium ulcerans toxic macrolide, mycolactone modulates the host immune response and cellular location of M. ulcerans in vitro and in vivo.Cell Microbiol. 2005 Sep;7(9):1295-304. doi: 10.1111/j.1462-5822.2005.00557.x. Cell Microbiol. 2005. PMID: 16098217
-
Buruli ulcer: emerging from obscurity.Lancet. 2006 Jun 3;367(9525):1849-58. doi: 10.1016/S0140-6736(06)68807-7. Lancet. 2006. PMID: 16753488 Review.
-
[Role of mycolactone in the nerve damage of Buruli ulcer (Mycobacterium ulcerans infection)].Nihon Hansenbyo Gakkai Zasshi. 2011 Feb;80(1):5-10. doi: 10.5025/hansen.80.5. Nihon Hansenbyo Gakkai Zasshi. 2011. PMID: 21404590 Review. Japanese.
Cited by
-
Recombinant Antibodies against Mycolactone.Toxins (Basel). 2019 Jun 17;11(6):346. doi: 10.3390/toxins11060346. Toxins (Basel). 2019. PMID: 31212961 Free PMC article.
-
Buruli ulcer: reductive evolution enhances pathogenicity of Mycobacterium ulcerans.Nat Rev Microbiol. 2009 Jan;7(1):50-60. doi: 10.1038/nrmicro2077. Nat Rev Microbiol. 2009. PMID: 19079352 Review.
-
Spontaneous Healing of Mycobacterium ulcerans Lesions in the Guinea Pig Model.PLoS Negl Trop Dis. 2015 Dec 1;9(12):e0004265. doi: 10.1371/journal.pntd.0004265. eCollection 2015 Dec. PLoS Negl Trop Dis. 2015. PMID: 26625302 Free PMC article.
-
Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease.Antimicrob Agents Chemother. 2010 Sep;54(9):3678-85. doi: 10.1128/AAC.00299-10. Epub 2010 Jun 21. Antimicrob Agents Chemother. 2010. PMID: 20566765 Free PMC article. Clinical Trial.
-
Buruli ulcer disease: prospects for a vaccine.Med Microbiol Immunol. 2009 May;198(2):69-77. doi: 10.1007/s00430-009-0109-6. Epub 2009 Feb 7. Med Microbiol Immunol. 2009. PMID: 19198877 Review.
References
-
- Abalos, F. M., J. Aguiar, Sr., A. Guedenon, F. Portaels, and W. M. Meyers. 2000. Mycobacterium ulcerans infection (Buruli ulcer): a case report of the disseminated nonulcerative form. Ann. Diagn. Pathol. 4:386-390. - PubMed
-
- Adusumilli, S., A. Mve-Obiang, T. Sparer, W. Meyers, J. Hayman, and P. L. Small. 2005. Mycobacterium ulcerans toxic macrolide, mycolactone modulates the host immune response and cellular location of M. ulcerans in vitro and in vivo. Cell. Microbiol. 7:1295-1304. - PubMed
-
- Asiedu, K., and S. Etuaful. 1998. Socioeconomic implications of Buruli ulcer in Ghana: a three-year review. Am. J. Trop. Med. Hyg. 59:1015-1022. - PubMed
-
- Bean, A. G., D. R. Roach, H. Briscoe, M. P. France, H. Korner, J. D. Sedgwick, and W. J. Britton. 1999. Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J. Immunol. 162:3504-3511. - PubMed
-
- Bendtzen, K. 1988. Interleukin 1, interleukin 6 and tumor necrosis factor in infection, inflammation and immunity. Immunol. Lett. 19:183-191. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials